Drug intelligence / Profile preview

LG002

Development stage: Phase 1
Lead developer: Laboratoires Genévrier
Modality: Cell Therapies
Administration: Grafted

Overview

LG002 is a cellularised dermal substrate developed by Laboratoires Genévrier for the treatment of severe burn injury. It is designed to be grafted onto excised full-thickness burn areas, serving as a temporary covering to replace allografts. Following its application, the dermal substrate is subsequently covered with a thin skin meshed autograft, facilitating tissue regeneration and wound healing.

Other names: dermal substrate cellularised LG002

Beyond the preview

Go deeper on LG002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LG002.

Explore the full profile